TCRT
Income statement / Annual
Last year (2023), Alaunos Therapeutics, Inc.'s total revenue was $5,000.00,
a decrease of 99.83% from the previous year.
In 2023, Alaunos Therapeutics, Inc.'s net income was -$35.14 M.
See Alaunos Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$5,000.00
|
$2.92 M
|
$398,000.00
|
$0.00
|
$0.00
|
$146,000.00
|
$6.39 M
|
$6.86 M
|
$4.33 M
|
$1.37 M
|
| Cost of Revenue |
$4.80 M |
$2.76 M |
$740,000.00 |
$1.13 M |
$629,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$4.80 M |
$163,000.00 |
-$342,000.00 |
-$1.13 M |
-$629,000.00 |
$146,000.00 |
$6.39 M |
$6.86 M |
$4.33 M |
$1.37 M |
| Gross Profit Ratio |
-959.6 |
0.06 |
-0.86 |
0 |
0 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$16.28 M
|
$25.02 M
|
$49.64 M
|
$52.70 M
|
$38.33 M
|
$34.13 M
|
$45.08 M
|
$157.79 M
|
$106.79 M
|
$32.71 M
|
| General & Administrative
Expenses |
$12.22 M
|
$13.14 M
|
$27.56 M
|
$27.67 M
|
$19.53 M
|
$19.92 M
|
$14.80 M
|
$14.38 M
|
$17.65 M
|
$12.17 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.22 M
|
$13.14 M
|
$27.56 M
|
$27.67 M
|
$19.53 M
|
$19.92 M
|
$14.80 M
|
$14.38 M
|
$17.65 M
|
$12.17 M
|
| Other Expenses |
$971,000.00 |
$529,000.00 |
-$1.20 M |
$385,000.00 |
$813,000.00 |
$631,000.00 |
$465,000.00 |
$134,000.00 |
$12,000.00 |
-$5,000.00 |
| Operating Expenses |
$29.47 M |
$38.16 M |
$77.21 M |
$80.36 M |
$57.86 M |
$54.05 M |
$59.88 M |
$172.17 M |
$124.43 M |
$44.87 M |
| Cost And Expenses |
$34.27 M |
$38.16 M |
$77.21 M |
$80.36 M |
$57.86 M |
$54.05 M |
$59.88 M |
$172.17 M |
$124.43 M |
$44.87 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.92 M |
$3.15 M |
$1.18 M |
$0.00 |
$0.00 |
-$789,000.00 |
$830,000.00 |
-$10,000.00 |
-$12,000.00 |
-$11.72 M |
| Depreciation &
Amortization |
$2.32 M
|
$2.76 M
|
$2.60 M
|
$1.13 M
|
$629,000.00
|
$573,000.00
|
$369,000.00
|
$290,000.00
|
$357,000.00
|
$462,000.00
|
| EBITDA |
-$30.90 M
|
-$31.82 M
|
-$74.97 M
|
-$78.85 M
|
-$117.17 M
|
-$53.33 M
|
-$53.12 M
|
-$165.01 M
|
-$119.73 M
|
-$43.50 M
|
| EBITDA Ratio |
-6180.8 |
-11.88 |
-191.13 |
0 |
0 |
-370.3 |
-8.17 |
-24.08 |
-27.72 |
-40.22 |
| Operating Income Ratio
|
-6853.4
|
-12.01
|
-194.85
|
0
|
0
|
-369.22
|
-8.37
|
-24.09
|
-27.72
|
-31.68
|
| Total Other
Income/Expenses Net |
-$873,000.00
|
-$2.63 M
|
-$1.20 M
|
$385,000.00
|
-$59.94 M
|
$789,000.00
|
-$830,000.00
|
$10,000.00
|
$12,000.00
|
$11.72 M
|
| Income Before Tax |
-$35.14 M |
-$37.73 M |
-$78.75 M |
-$79.98 M |
-$117.80 M |
-$53.12 M |
-$54.32 M |
-$165.30 M |
-$120.09 M |
-$31.78 M |
| Income Before Tax Ratio
|
-7028
|
-12.91
|
-197.87
|
0
|
0
|
-363.82
|
-8.5
|
-24.09
|
-27.72
|
-23.15
|
| Income Tax Expense |
$0.00 |
-$133,000.00 |
-$1.86 M |
-$1.13 M |
$60.12 M |
-$947,000.00 |
$2.13 M |
$114,000.00 |
-$12,000.00 |
-$23.44 M |
| Net Income |
-$35.14 M |
-$37.60 M |
-$76.89 M |
-$78.85 M |
-$177.92 M |
-$53.12 M |
-$54.32 M |
-$165.30 M |
-$120.09 M |
-$31.78 M |
| Net Income Ratio |
-7028 |
-12.87 |
-193.2 |
0 |
0 |
-363.82 |
-8.5 |
-24.09 |
-27.72 |
-23.15 |
| EPS |
-21.97 |
-25.97 |
-53.8 |
-56.42 |
-158.9 |
-55.52 |
-59.5 |
-190.15 |
-143.63 |
-47.14 |
| EPS Diluted |
-21.97 |
-25.97 |
-53.8 |
-56.42 |
-158.9 |
-55.44 |
-59.5 |
-190.15 |
-143.63 |
-47.14 |
| Weighted Average Shares
Out |
$1.60 M
|
$1.45 M
|
$1.43 M
|
$1.40 M
|
$1.12 M
|
$956,724.00
|
$912,921.00
|
$869,276.00
|
$836,107.00
|
$674,204.00
|
| Weighted Average Shares
Out Diluted |
$1.60 M
|
$1.45 M
|
$1.43 M
|
$1.40 M
|
$1.12 M
|
$958,067.00
|
$912,921.00
|
$869,276.00
|
$836,107.00
|
$674,204.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
